Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

Exclusion Criteria

• •Current participation in a clinical trial for the second-line treatment of prostate cancer
• •Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity
• •Patients having already started a second line treatment
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.